10-K: Marizyme, Inc. 10-K Filing: Details on Securities, Financials, and Future Strategy

Marizyme, Inc.'s 10-K filing provides a comprehensive overview of the company's securities, financial performance, and strategic direction, highlighting its focus on DuraGraft commercialization and other medical technologies.

Summary

• Marizyme, Inc. is a medical technology company focused on cardiac care, particularly coronary artery bypass graft (CABG) surgery.
• The company's key product, DuraGraft, is authorized for marketing in the U.S. as an intra-operative vascular conduit storage and flushing solution for CABG surgeries.
• DuraGraft also has CE marking for sales in the European Economic Area (EEA) and other countries.
• Marizyme is working on U.S. commercialization through hospital networks and direct sales, while continuing international sales through distributors.
• The company is also developing MAR-FG-001 for fat grafting procedures, but has paused or slowed development of other technologies like Krillase and MATLOC.
• As of March 24, 2023, Marizyme had 300,000,000 authorized common shares and 25,000,000 authorized preferred shares, with 40,768,191 common shares issued and outstanding.
• The company has issued warrants to purchase 3,000,000 shares of common stock in connection with the Somahlution acquisition.
• Convertible notes issued in a private placement can be converted into 8,269,228 shares of common stock as of March 24, 2023, with a conversion price of $1.75 per share.
• Class C Warrants may be exercised to purchase up to 16,538,486 shares of common stock as of March 24, 2023, at an exercise price of $2.25 per share or 75% of the price in a qualified financing.
• The company has also issued Class D Warrants and Placement Agent Warrants, with specific terms and conditions.
• Marizyme has a Stock Incentive Plan (SIP) with 7,200,000 shares reserved for issuance, with 350,000 shares of restricted common stock and options to purchase 3,925,943 shares granted as of March 24, 2023.
• The company is subject to anti-takeover provisions under Nevada law and its bylaws, which could delay or prevent a change of control.
• The company's transfer agent and registrar is Securities Transfer Corporation.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive developments (FDA approval, market potential) but significant concerns (financial losses, debt default, material weakness in controls). The overall sentiment is negative due to the financial instability and risks.

Positives

• DuraGraft has received FDA authorization for marketing in the U.S., which is a significant milestone.
• The company has a strong patent portfolio for DuraGraft, providing a competitive advantage.
• The company is targeting a large and growing market for CABG procedures.
• DuraGraft has shown clinical benefits, including reduced mortality and vein graft failure.
• The company is expanding its international marketing efforts through distribution partners.
• The company is developing MAR-FG-001, which has potential in the growing fat grafting market.

Negatives

• The company has incurred significant losses since inception and anticipates continued losses.
• The company has a material weakness in its internal controls over financial reporting.
• The company defaulted under the Convertible Notes, which could lead to acceleration of amounts owed and potential seizure of assets.
• The company has negative working capital and limited cash reserves.
• The company has a limited operational history and is dependent on third-party manufacturers.
• The company faces intense competition in the medical device market.
• The company has limited experience in commercializing products and may need to invest significant resources to develop these capabilities.

Risks

• The company may not be able to raise sufficient additional funding, which could force it to delay or abandon growth initiatives.
• The company may not be able to monetize intangible assets, which may result in the need to record an impairment charge.
• The company may not be able to effectively compete against other providers of medical devices.
• The company's products may not achieve market acceptance.
• The company may be subject to product liability lawsuits.
• The company may not be able to protect or enforce its intellectual property rights.
• The company may be dependent on third-party manufacturers.
• The COVID-19 pandemic has adversely impacted the company's supply chain and could materially affect its ability to conduct clinical trials and engage with third-party vendors.
• The company's efforts to obtain and maintain a listing of its common stock on the Nasdaq Capital Market may fail.
• Substantial future sales or issuances of the company's securities may depress the price of its common stock.

Future Outlook

The company expects to incur significant and increasing operating losses for the next several years as it expands its acquisition efforts, continues clinical trials, acquires or licenses technologies, advances other medical devices into clinical development, completes clinical trials, seeks regulatory approval and, if it receives FDA approval, commercializes its products. The company anticipates that once it commences marketing and sales operations for DuraGraft in the U.S., it will be able to generate sustainable revenue growth and continue the expansion of DuraGraft and expedite the development of MAR-FG-001 into medical products.

Management Comments

• The company intends to maintain the Krillase assets for potential future development and commercialization or disposition.
• The company intends to commercialize DuraGraft in the U.S. primarily through hospital integrated networks using its own direct sales force.
• The company anticipates that once it commences marketing and sales operations for DuraGraft in the U.S., it will be able to generate sustainable revenue growth and continue the expansion of DuraGraft and expedite the development of MAR-FG-001 into medical products.

Industry Context

The medical device market is highly competitive, with many companies pursuing the development of medical devices that target the same conditions as Marizyme. The company's success will depend on its ability to compete effectively against other providers of medical devices, particularly those with greater resources. The company is also subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject it to penalties if it fails to comply with applicable regulatory requirements.

Comparison to Industry Standards

• Marizyme's DuraGraft is unique in that it is the first and only FDA-cleared medical device for use as an intra-operative vascular conduit storage and flushing solution during CABG surgeries, setting it apart from competitors who may offer similar solutions but lack this specific clearance.
• The company's focus on hospital integrated networks for commercialization is a common strategy in the medical device industry, but the success of this approach will depend on Marizyme's ability to establish strong relationships and secure contracts with these networks.
• The company's reliance on third-party manufacturers is also a common practice in the industry, but it introduces risks related to supply chain disruptions and quality control.
• Compared to larger, more established medical device companies, Marizyme has limited resources and a shorter operational history, which may make it more challenging to compete effectively.
• The company's financial performance, with significant losses and negative working capital, is not uncommon for early-stage medical device companies, but it highlights the need for additional funding and revenue generation.
• The company's focus on the development of MAR-FG-001 for fat grafting procedures is aligned with the growing trend of non-invasive aesthetic techniques in skin rejuvenation, but the company will need to demonstrate the superiority of its technology compared to existing solutions.

Management Changes

Corporate Governance

Legal Proceedings

• The company was involved in litigation with Nicholas DeVito, a former Interim Chief Executive Officer and Interim Chief Financial Officer, which was settled in November 2022.
• The company was involved in litigation with Amy Chandler, a former employee, which was voluntarily dismissed without prejudice in November 2022.
• The company was involved in litigation with Dr. Neil Campbell and Bruce Harmon, former officers, which was dismissed with prejudice in April 2022.

Related Party Transactions

• The company has lease arrangements for office and laboratories facilities with a related party.
• The company has incurred professional fees with related parties for consulting services.
• The company has accrued royalties payable to former stockholders of Somahlution, who are related parties.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial instability.
• Employees may be affected by potential cost-cutting measures and changes in management.
• Customers may experience delays or disruptions in product supply due to the company's reliance on third-party manufacturers.
• Suppliers may face increased credit risk due to the company's financial challenges.
• Creditors face the risk of non-payment due to the company's default under the Convertible Notes.

Next Steps

• The company will proceed with plans to commercialize DuraGraft in the United States.
• The company will continue to generate international revenue growth from sales of DuraGraft.
• The company will continue the development of MAR-FG-001 fat grafting technology and products.
• The company will seek to obtain additional financing from time to time.

Key Dates

Keywords

DuraGraft, CABG, medical device, vascular conduit, fat grafting, MAR-FG-001, convertible notes, warrants, FDA, CE marking, clinical trials, intellectual property, financial reporting, internal controls, capital raise